Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, …

… B Heemskerk, P Kvistborg, TN Schumacher: The cancer antigenome EMBO J 32: 194–
203,2013 … RS Andersen, P Kvistborg, TM Frøsig, etal: Parallel detection of antigen-specific …

Fluorescently labeled multimeric complexes of peptide-MHC, the molecular entities
recognized by the T cell receptor, have become essential reagents for detection of antigen-specific …

Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free
survival of stage III melanoma patients 1 , 2 . In stage IV disease, the combination of ipilimumab …

Malignant transformation of cells depends on accumulation of DNA damage. Over the past
years we have learned that the T cell–based immune system frequently responds to the …

The transfer of T cell receptor (TCR) genes into patient T cells is a promising approach for
the treatment of both viral infections and cancer. Although efficient methods exist to identify …

From a technical point of view a flow cytometer is a light detection device capable of detecting
photons of different wavelengths over a high dynamic range. In order to achieve a high …

Adoptive T cell therapy (ACT) using ex vivo–expanded autologous tumor-infiltrating lymphocytes
(TILs) can mediate complete regression of certain human cancers. The impact of TIL …

Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing
with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, …

A variety of species of bacteria are known to colonize human tumours 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8
, 9 , 10 – 11 , proliferate within them and modulate immune function, which ultimately affects …